Accessibility Menu
An2 Therapeutics logo

An2 Therapeutics(NASDAQ) ANTX

Market Cap$192.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-65%
5 YearN/A
1 Year+405%
1 Month+14%
$5.37
+0.75%
+0.04Today
After hours$5.26-$0.11 (-2.05%)
An2 Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 5.352026-07-31
An2 Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.74%USD 4.922026-07-24
1 month+13.83%USD 4.702026-07-01
3 month+14.32%USD 4.682026-05-01
Year to date+369.3%USD 1.142025-12-31
1 year+404.72%USD 1.062025-07-31
3 year-34.76%USD 8.202023-08-01
Since inception-65.26%USD 15.402022-03-25

An2 Therapeutics Financials at a Glance

Market Cap

$192.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$34.55M

EPS (TTM)

-$1.10

P/E Ratio

-4.84

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$5.37

Volume

250,627.771

Open

$5.37

Previous Close

$5.35

Daily Range

$5.26 - $5.66

52-Week Range

$1.00 - $6.91

Estimated Earnings Date

Aug 11, 2026

ANTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About An2 Therapeutics

AN2 Therapeutics develops medicines for rare and serious infectious diseases. Its main drugs aim to help people with hard-to-treat lung and tropical infections. The company’s work targets patients with few existing treatment options.

What’s in the Medicine Cabinet?

  • Epetraborole: Oral drug in trials for chronic lung infections and melioidosis, a tropical disease. (0% of revenue; company has no product sales)
  • AN2-502998: Early-stage treatment for Chagas disease, a chronic infection common in Latin America. (0% of revenue)
  • Boron-based Compounds: Research programs for other rare infections and some cancer types. (0% of revenue)
  • Collaborative Research: Joint projects with universities and non-profits to develop new anti-infective drugs. (0% of revenue)
  • Licensing Agreements: Rights to develop and sell certain drugs from Anacor Pharmaceuticals and Brii Biosciences. (0% of revenue)

Growth and Expansion: The Road So Far

  • Signed exclusive license with Anacor Pharmaceuticals for boron-based drugs (2019).
  • Entered China-focused partnership with Brii Biosciences (2019).
  • Launched Phase 1 trial for Chagas disease drug in May 2025.
  • Started collaboration with Drugs for Neglected Diseases initiative in July 2025.
  • Secured grants from the Bill and Melinda Gates Foundation for tuberculosis and malaria research (2023-2025).

What Makes AN2 Stand Out in the Lab Crowd?

AN2 uses boron-based chemistry to target infections that lack good treatments. The company partners with global health groups to reach underserved markets. Its focus on rare diseases and non-traditional funding sources shapes its business model.

Five Things You Need to Know

  • No product revenue as of Q2 2025; all income from grants and financing.
  • Net loss was $7 million in Q2 2025, improving 54.6% from Q2 2024.
  • Cash and investments fell 49.7% to $32 million from Q2 2024 to Q2 2025.
  • Workforce reduced by 50% in August 2024 to extend cash runway.
  • Company faces ongoing funding needs and relies on external capital.

Bottom Line

AN2 Therapeutics is a small biotech focused on rare infectious diseases. Its future depends on clinical progress and continued access to funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

21

CEO

Eric Easom, MBA

Website

www.an2therapeutics.com

Headquarters

Menlo Park, CA 94027, US

ANTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-52.35%

Return on Capital

-71.82%

Return on Assets

-39.49%

Earnings Yield

-20.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$192.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.02M

Volume

250.63K

Avg. Volume

290.05K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$37.12M

EBITDA

-$35.85M

Operating Cash Flow

-$31.28M

Capital Expenditure

$0.00

Free Cash Flow

-$31.28M

Cash & ST Invst.

$85.29M

Total Debt

$0.00

An2 Therapeutics Performance Analysis

An2 Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
An2 Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
An2 Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2047.0%
20232023-12-31USD -2.7424.4%
20242024-12-31USD -1.72-37.3%
20252025-12-31USD -1.16-32.3%
An2 Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3040.0%
Q32025-09-30-47.6%
Q42025-12-316.5%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$192.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.18M

N/A

Employees

21

N/A

Net Income

-$10.03M

+5.8%

EBITDA

-$10.03M

+5.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$85.29M

+27.2%

Total Debt

$0.00

N/A

Accounts Receivable

$300.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-39.49%

N/A

Return on Invested Capital

-45.31%

N/A

Free Cash Flow

-$12.07M

-13.6%

Operating Cash Flow

-$12.07M

-13.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QTTBQ32 Bio Inc.
$15.68+0.77%
BOLDBoundless Bio, Inc.
$2.50+0.00%
VRCAVerrica Pharmaceuticals Inc.
$5.22-0.76%
SABSSAB Biotherapeutics, Inc.
$3.57+0.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ANTX

What is the current price of An2 Therapeutics?

An2 Therapeutics is trading at $5.35 per share.

What is the 52-week range for An2 Therapeutics?

Over the past 52 weeks, An2 Therapeutics has traded between $1.00 and $6.91.

How much debt does An2 Therapeutics have?

As of the most recent reporting period, An2 Therapeutics reported total debt of $0.00.

How much cash does An2 Therapeutics have on hand?

An2 Therapeutics reported $53.49M in cash and cash equivalents in its most recent financial results.

What is An2 Therapeutics’s dividend yield?

An2 Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services